CTOs on the Move

Essia Health

www.essiahealth.com

 
Our story begins in 2005, with a healthcare professional, Dr. Kathleen Myers. She was hired to help open a new, paperless hospital using multiple EMRs and CPOE. A dedicated emergency medicine physician, she knew that every minute counted and worried that “going paperless” would take valuable time away from patients — which was unacceptable. She challenged herself to find a solution. Her answer was a scribe program. She championed development of this for her emergency department, and scribes quickly became an indispensable part of her practice of medicine. So much so, that Dr. Myers sought the support of like-minded individuals with ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Lexicomm International

Lexicomm International, Ltd. is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medefield

Medefield is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Med-Response Inc

Med-Response Inc is a Bluefield, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Research Diets

Research Diets is a New Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.